MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
|Jun 12, 2019||MannKind to Present at the JMP Securities Life Sciences Conference… More|
|Jun 09, 2019||MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions… More|
|Jun 03, 2019||Afrezza® (insulin human) Inhalation Powder Approved in Brazil… More|
|May 16, 2019||MannKind Announces Afrezza® Distribution Agreement in Australia… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.